Objectives The aim of the study was to identify any unexpected clinical events associated with starting the new CFC-free formulation of 
Introduction
Atrovent â chlorofluorocarbon (CFC)-free metered dose inhaler (MDI) is a CFC-free formulation of the short-acting anticholinergic bronchodilator, ipratropium bromide. Ipratropium bromide is indicated for 'the regular treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic asthma'. [1] The CFC-free formulation of Atrovent â MDI was introduced after a decision to phase out CFC propellants due to environmental concerns over the ozone layer. [2] Hydrofluoroalkane 1,1,1,2-tetrafluoroethane (HFA 134a) is an alternative propellant for MDIs that has been developed and is used in the CFC-free formulation of Atrovent â MDI. [2] An active surveillance cohort study was requested by regulators of the manufacturer with an overall aim to monitor the introduction of the CFC-free formulation in general practice in England, following the switch from the CFC containing formulation of Atrovent â MDI. The primary objective of the study was to identify any unexpected clinical events associated with starting the CFC-free formulation of Atrovent â MDI, including paradoxical bronchospasm. The secondary objective of the study was to monitor the safety of patients previously and newly exposed (Atrovent â na€ ıve) to Atrovent â CFC-free MDI in the immediate postmarketing period. Of particular interest for both the primary and secondary objectives were respiratory events reported within the first 3 months after starting treatment, compared to the 3 months prior to starting treatment.
To complement the information regarding safety collected from clinical studies and spontaneous reporting schemes, the Drug Safety Research Unit (DSRU) carries out postmarketing surveillance studies of newly marketed drugs with widespread use in primary care in England, using the observational cohort technique known as Modified Prescription-Event Monitoring (M-PEM), which retains all the strengths of the standard observational cohort technique of Prescription-Event Monitoring (PEM), [3] but offers more targeted safety surveillance through use of bespoke questionnaires. Such a design was used for this study to monitor the introduction of Atrovent â CFC-free inhaler. The main aim of the study was to identify any unexpected clinical events associated with starting the new CFC-free formulation of Atrovent â MDI in general practice in England.
Methods
An M-PEM study was conducted to monitor the safety of Atrovent â CFC-free MDI as used in general practice in
England. The methods of M-PEM are reported elsewhere. [4] Briefly, patients were identified by means of data from dispensed National Health Service (NHS) prescriptions, written by General Practitioners (GPs) in England between May 2004 and February 2005. These prescription data were supplied in confidence to the DSRU by the NHS Business Services Authority (NHSBSA).
At least 3 months after the first identified prescription was issued for each patient, the prescribing doctor was sent a questionnaire by post. GPs were asked to select the prescribing indication from a list provided on the questionnaire. Where two indications were selected, these were both recorded as the prescribing indication, for example COPD/Asthma. GPs were also asked questions about when treatment was started and stopped (if applicable), relevant past medical history and any events experienced by the patient in the 3 months prior to treatment, during treatment and/or in the 30 days after stopping. All indications, relevant past medical history and events reported on questionnaires were coded onto a DSRU database using a hierarchical event dictionary arranged in a system organ classification, containing higher, lower and doctor summary level terms.
Ethics
This study was conducted in accordance with national and international guidelines. [5] [6] [7] In addition, under Section 251 of the NHS Act 2006, the DSRU has received support from the Ethics and Confidentiality Committee of the National Information Governance Board to gain access to and process patient identifiable information without consent for the purposes of medical research (October 2009).
Sample size calculation
To find statistically significant differences between number of events occurring prior to and after the first prescription for Atrovent â CFC-Free MDI, for events occurring during the pre-exposure period at a frequency of 1/1000 patients and in the postexposure period at 3/ 1000 patients with a power of at least 80%, for a confidence of 99%, we needed to recruit at least 12 634 users of Atrovent â CFC-Free MDI (EpiInfo V3.5.1, Atlanta, GA, USA).
Data analysis
Summary statistics were produced for patient characteristics (including past medical history), prescribing information and medical event data at aggregate level. Crude odds ratios were calculated for cohort and drug utilisation characteristics comparing na€ ıve users to switchers using STATA v12 (StataCorp LP, College Station, TX, USA). Incidence density rates were calculated for all events reported during treatment for the overall 3 month posttreatment period (ID [1] [2] [3] Figure 1 ). For individuals who discontinued treatment during the high-risk period, a nominal risk period was used equal to the average high-risk period observed in the study. If any individual died, a nominal observation period was used based on the average time from event to discharge in other cases. IDs were also calculated for the 3 month period prior to starting Atrovent â CFC-Free MDI-the 'reference period' (ID R ). Incidence density rate ratios were calculated (99% confidence intervals [CI]) for events, comparing incidence density rates in the high-and low-risk periods to the reference period. This examined the null hypothesis that the rate for the event was not increasing or decreasing between the two time periods. [8] The first report of an event for the prior (reference period) and post (3 months after starting treatment) period was included for the incidence density rate ratios, which was an unmatched analysis.
As IDs for the overall cohort may sometimes mask significant signals in specific risk groups (Atrovent â na€ ıve, switchers, asthma patients and COPD patients [not mutually exclusive]), these subgroups had IDs calculated and compared according to strata for respiratory events (ID 1 / ID R , ID 2-3 /ID R and ID 1-3 /ID R for lower respiratory tract infection, dyspnoea and asthma worse). To minimise confounding, a matched pair analysis was conducted which calculated the risk ratio in the 3 month observation period pre-and post-starting Atrovent â CFC-Free MDI for a priori selected respiratory events at lower level term. Risk ratios (99% CI) were calculated to compare the frequency of selected events in the 'before' and 'after' periods. The use of a matched analysis improved the power of the statistical test from the unmatched analysis because of the controlling of the matched covariates.
Results

Cohort accrual data and characteristics
Dispensed prescriptions were written by 12 771 GPs. Of the 25 706 questionnaires posted to the prescribing GPs, 51.4% (13 211) questionnaires returned contained valid information (16 186 questionnaires returned in total; 63%). The final study cohort comprised 13 211 patients (median age 70 years; 50.1% female). Cohort characteristics are presented in Table 1 . The majority of patients in the cohort were switchers from Atrovent â CFC inhaler (8390, 63.5% of cohort) ( Table 1) . The most frequently reported indication for prescribing Atrovent â CFC-Free MDI was COPD (n = 8408, 63.6% of cohort; 64.4% where indication specified and only in adults), followed by asthma (n = 3161, 23.9% of cohort; 24.2% where indication specified). Further information on the drug utilisation characteristics of the cohort is provided in Table 2 . The season when Atrovent â CFC-free inhaler was started was of interest as the winter season is associated with an increased incidence of influenza and respiratory tract infections, [9] [10] [11] which may result in an increased number of events during this period or may be related to the indication for treatment. The majority of patients (59.6% of cohort) started treatment with Atrovent â CFCfree in the autumn and winter months.
Respiratory events and incidence density ratios for whole cohort
The respiratory system organ class had the most events reported overall (4617, 33.3% of events reported), with the majority of these events occurring post-treatment (2455, 53.2% of respiratory events reported). There were no reports of paradoxical bronchospasm in the study. The event with the highest incidence density rate (ID) in the first month of treatment was 'Lower respiratory tract infection' (ID 1 = 25.25). The incidence density rate for the total risk period compared to the reference period (ID 1-3 /ID R ) revealed significantly increased rates for 'Lower respiratory tract infection' (ID 1-3 /ID R = 1.28, 99% CI: 1.12, 1.46) and 'COPD' (ID 1-3 /ID R = 1.29, 99% CI: 1.10, 1.51) in the total risk period. The corresponding ID ratios for the first month of treatment compared to the reference period (ID 1 /ID R ), revealed a significantly increased rate for 'Lower respiratory tract infection' in the first month of treatment ('high-risk period') compared to the reference period (ID 1 /ID R = 1.42, 99% CI: 1.19, 1.69), and also in the 'low-risk period' compared with the reference period (ID 2-3 /ID R = 1.20, 99% CI: 1.03, 1.40), although the point estimate was slightly lower. The rate was also significantly increased in the first month of treatment for 'COPD' compared with the reference period (ID 1 /ID R = 1.52, 99% CI: 1.24, 1.86), but there was no significant difference observed for the low-risk period (ID 2-3 /ID R = 1.17, 99% CI: 0.97 to 1.40). Of note, the dictionary higher level term 'COPD' encompasses exacerbations of the disease as well as new diagnoses. In the Atrovent â CFC MDI switchers subset, an event rate significantly associated with the high-risk period compared with the reference period was for the event 'Lower respiratory tract infection' (Figure 2 ). However, unlike the naive subset, this event had a rate which was also significantly higher in the low-risk period compared with the reference period. In addition, the rate of 'COPD' was significantly associated with both the high-and lowrisk period (ID 1 /ID R = 1.66, 99% CI: 1.31, 2.11; ID 2-3 / ID R = 1.26, 99% CI: 1.02, 1.56). In Atrovent â CFC MDI switchers, the rate of 'Asthma worse' was associated with starting treatment in the highrisk period compared with the reference period, although of borderline significance. The rate of 'dyspnoea' was not significantly increased or decreased during the high-risk, low-risk or total risk periods for both Atrovent â na€ ıve and switcher patients.
Matched analysis results
For all patients in the matched analysis, risk of hospital admissions (RR = 1.35, 99% CI: 1.11, 1.65) was significantly greater in the 3-month period after starting than before (Table 3) . Also, patients were at greater risk of taking high dose oral steroids (RR = 1.21, 99% CI: 1.11 to 1.32) in the 3 months post-treatment, compared to the 3 months prior to treatment. After stratification by prior use of Atrovent â CFC MDI, naive users showed a decrease in the risk of dyspnoea after starting treatment with Atrovent â CFC-free, compared to the reference period. Atrovent â na€ ıve patients had a significantly increased risk of respiratory hospital referrals after starting treatment compared to the reference period. In contrast to Atrovent â naive patients, for Atrovent â switcher patients, dyspnoea was not shown to be significantly associated with the risk period or the reference period. However, for switchers there was an observation of more frequent use of high dose steroids after starting treatment than prior to starting treatment.
Stratified incidence density rate ratios for COPD and Asthma patients
To determine if the indication for treatment had an effect on the incidence density rate ratios, these were further stratified into COPD and asthma patients (Figure 2) . After stratification by indication, the trend for an increased rate of LRTI after starting treatment was only Chracteristics highlighted in bold were used as the baseline for comparison of the odds. 
Discussion
Main study findings Elevated rates of respiratory events in the period after starting treatment in switcher and COPD patients were observed, along with decreased rates of dyspnoea in the period after starting treatment in na€ ıve patients. As the main aim of the study was to identify any unexpected clinical events associated with starting the new CFC-free formulation of Atrovent â MDI in general practice in England, these results clearly address this aim. Overall, the before and after study design for examining events was successful for estimating the effect of introducing the CFC-free inhaler into England.
Strengths and limitations
One of the major strengths of PEM methodology is that it is non-interventional and does not influence the prescribing practices of GP's. There are also no exclusion criteria, that is all patients prescribed and dispensed the study drug are eligible for inclusion.
However, of the questionnaires sent to GPs (25 706), 16 186 (63%) were returned. This study did not assess the impact of non-response bias, but this response rate is comparable to response rates reported elsewhere for GP postal surveys [12] and higher than the reporting rates of suspected ADRs in the Yellow Card Scheme. [13, 14] Additionally, under reporting of adverse events, including serious and fatal events, is possible in PEM as not all events may be reported to the GP by the patient. Also, as an observational study, it is not possible to estimate the amount of patient compliance with Atrovent â CFC-free
MDI.
The delay in submission of this study was due to several factors: the time required to review questionnaires, code data, perform data cleaning and analysis. There was also a requirement to perform further data analysis, stratifying by indication. However, we feel this study is still useful for pharmacy practice and that it is important to communicate our findings regarding respiratory events in this patient population. The results still contribute additional information to the current knowledge about this medication.
Event profiles
The majority of patients in the cohort were switchers from Atrovent â CFC MDI (8390, 63.5%). It was observed that switchers from Atrovent â CFC MDI were more likely Chracteristics highlighted in bold were used as the baseline for comparison of the odds.
to be adults, have an indication of COPD and have moderate/severe disease. Due to the pathological differences between asthma and COPD alone, patients would experience different events, [15, 16] but additionally age and disease severity can also create different event profiles. [17] [18] [19] The high-risk period was associated with increased reports of both asthma worse and COPD in switchers. The same observation for COPD was also observed for the entire cohort. 'COPD' is an indication-related higher and lower level term which incorporates the doctor summary terms 'COPD exacerbation' and 'COPD uncontrolled', among other terms. As COPD is a progressive disease which can only be controlled and not improved, [20] it would be expected for patients to experience these events whilst using Atrovent â CFC-free inhaler.
'Asthma worse' is an indication-related event that indicates a patient's asthma is not being controlled and is worsening. This indicates that a patient will need to 'step up' their therapy [21] or change their therapy in an attempt to control their symptoms. Unlike COPD patients, asthma is a disease which can be improved with the right combination of therapy. [15, 21] An explanation for the association Figure 2 Plot of rate ratios and 99% confidence intervals for respiratory events, stratified by prior Atrovent CFC MDI use and indication. with the high-risk period for switchers from Atrovent â CFC MDI is the seasonality of respiratory tract infections resulting in increased acute exacerbations and the fact that many patients started Atrovent â CFC-free inhaler in the winter months. [9] [10] [11] For both subsets of patients, the frequency of lower respiratory tract infection was higher after starting treatment than prior. This may be due to calendar time of starting treatment (seasonality) because the majority of patients (59.6%) started treatment with Atrovent â CFC-free MDI in the autumn and winter months. The winter season is associated with an increased incidence of influenza and respiratory tract infections, [9] [10] [11] 22] which could provide one explanation of the results of this unmatched analysis. This effect has been seen in another PEM study conducted on the introduction of the CFC-free formulation of Ventolin â Evohaler into the UK population. [23] Another explanation is protopathic bias. This occurs when the pharmacological agent is prescribed for early manifestation of a condition that has not yet been diagnosed, but which then appears to be the cause of the condition when it is eventually diagnosed. [24] Thus, our hypothesis is that both subgroups of patients sought medical advice because of worsening respiratory function, which later turned out to be associated with lower respiratory tract infection, and this diagnosis was recorded at the same time as starting the new CFC-free version of Atrovent â.
The results of the matched analysis support the observations regarding differences in the event profile between switchers from Atrovent â CFC MDI compared to those who are Atrovent â naive, particularly in terms of severity of indication, ongoing monitoring/referrals and admissions to hospital. The matched analysis produced significant risk ratios for use of high dose oral steroids and hospital admissions for the whole cohort. The significant risk ratio for high dose oral steroids may have been confounded by the increased rate of concomitant lower respiratory tract infections, as patients may require oral steroids to control their disease whilst fighting the infection. [25] Due to the elderly population in the cohort, and the high number of patients with COPD, hospital admissions are not unexpected as patients may have experienced exacerbations of COPD requiring admission, [26] or any other condition relating to age which required admission. Additionally, the high number of admissions may have been related to the season most patients started Atrovent â CFC-free (winter), which is associated with increased hospitalisation due to respiratory infections. [9] [10] [11] 22] Stratified risk estimates of respiratory events such as dyspnoea and respiratory hospital referrals indicate effect modification by past use of Atrovent â CFC
MDI. This provides further evidence that when undertaking surveillance studies, it is important to present and discuss issues concerning safety and use separately in these subsets.
The observation of elevated rates of respiratory events in the period after starting treatment in switcher and COPD patients could be suggestive of a period of increased risk after changing treatment regimen in these patients. However, an alternative explanation could be that COPD patients are more likely to experience dyspnoea which cannot improve over time, due to the nature of the disease. In contrast, the cause of dyspnoea in asthma patients can be treated and so improve over time.
The observation of decreased risk of dyspnoea in the period after starting treatment in na€ ıve patients could be suggestive of a protective effect of Atrovent CFC-free inhaler. A possible explanation for this is that patient's respiratory disease was uncontrolled prior to starting the inhaler, resulting in a higher event rate compared to after starting treatment.
Conclusion
The results of this study suggest possible effect modification of risk as a result of prior Atrovent â CFC MDI use, and this should be taken into consideration when evaluating the risk benefit profile of new CFC-free formulation inhalers. Overall, Atrovent â CFC-free MDI appeared to be reasonably well tolerated in the immediate postmarketing period and the safety profile appeared to be similar to that of the CFC formulation MDI.
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